Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

CSL Limited (ASX: CSL): Navigating $7.1 Billion in Impairments — Should Investors Keep This Healthcare Giant on Their Radar?

• Pre-tax asset impairments of $7.1 billion recognised in FY26 triggered a reported NPAT loss of $2.6 billion.

Sonal Goyal | 09 September 2026

Biome Australia (ASX:BIO) Expands Its Top-Selling Probiotic Range With New 60-Pack Formats

Biome Daily Probiotic is a six-strain formulation containing 9 billion live bacteria per capsule, designed for adults and formulated to support digestive and immune health. Its combination of the HEAL9 and 8700:2 strains has been examined in randomised, double-blind, placebo-controlled trials involving more than …

Sonal Goyal | 09 September 2026

IMEXHS (ASX:IME): Cloud Radiology Software Wins Mexico Tender as Agentic AI Platform Launches

2. Recent FY26 updates included half-year results, an agentic AI platform launch and a public tender win in Mexico.

Sonal Goyal | 09 September 2026

TrivarX (ASX:TRI): Stabl-Im Mental Health Program Hits Clinical Supply Milestone — What Investors Need to Know

2. Recent updates included engagement of a contract research organisation and achievement of a clinical-trialSupplymilestone.

Sonal Goyal | 09 September 2026

4DMedical (ASX:4DX): XV Lung Imaging and Imbio Platform Advance as Respiratory AI Market Heats Up

2. FY2026 results provide the latest operating update, while ongoing quarterly reporting tracks commercial progress.

Sonal Goyal | 09 September 2026

Ceretas (ASX:CTS): Clinical Trial Sites Expand as This Newly Listed Healthcare Company Builds Its Case

2. Recent announcements include FY2026 reporting and ethics-committee approval for additional clinical-trial sites.

Sonal Goyal | 09 September 2026

Control Bionics (ASX:CBL): German Reimbursement Progress and US iOS Opportunity — Neurotechnology at a Crossroads

2. Recent updates highlighted commercial momentum, German reimbursement progress, a US iOS speech-device opportunity and strategic management changes.

Sonal Goyal | 09 September 2026

BlinkLab (ASX:BB1): Smartphone ADHD Diagnostics Clear European Study — Commercialisation in Sight?

2. Recent FY26 updates highlighted positive European ADHD study results, continued clinical development and a newly strengthened board.

Sonal Goyal | 09 September 2026

Artrya (ASX:AYA): AI Coronary Imaging Technology Targets Global Heart Disease Diagnosis Market

2. Recent FY26 reporting and operational updates indicate continued progress toward commercialisation and international adoption.

Sonal Goyal | 09 September 2026

Oneview Healthcare (ASX:ONE): AI Bedside Assistant and Epic Integration — Can Digital Hospitals Drive the Next Growth Phase?

• Bedside Hub announced: a new Epic MyChart integration opening a newRevenuechannel within the world's dominant EHR ecosystem

Sonal Goyal | 08 September 2026
Support

Hi! How can we help you today?

Loading…